Prior research has shown that CANDI with LCL‐161 activates the non‐canonical NFkB pathway that stimulates DC.[10] The LNP was designed to have a long circulation half‐life so that the nanoparticle would accumulate in phagocytic myeloid cells in the tumor microenvironment and its draining lymph nodes. Here, NFKB1 is linked to neoplasm.